Klinische Studie NCT07063745 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Klinische Studie NCT07063745 (Phase II/III) ist «rekrutierend» auf ClinicalTrials.gov.

Erkrankung: Metastatic Non-small Cell Lung Cancer With MTAP Deletion · Registrierte Interventionen: BMS-986504, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel · Erfasste Daten (Quelle): 2026-01-02, 2031-08-12, 2025-07-14, 2026-10-23.

Studienzusammenfassung (Quelle: ClinicalTrials.gov, Originaltext auf Englisch):

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Quelle: https://clinicaltrials.gov/study/NCT07063745